SNIBE(SZ:300832)2023-04-06 16:00Financial Performance - In 2022, the company's operating revenue reached ¥3,046,955,734.50, representing a 19.70% increase from ¥2,545,415,315.72 in 2021[11]. - The net profit attributable to shareholders was ¥1,327,918,359.24, a 36.38% increase compared to ¥973,696,489.03 in 2021[11]. - The net profit after deducting non-recurring gains and losses was ¥1,240,605,226.60, up 40.52% from ¥882,878,837.06 in 2021[11]. - The net cash flow from operating activities was ¥962,391,435.81, reflecting a 24.47% increase from ¥773,218,330.43 in 2021[11]. - The total assets at the end of 2022 amounted to ¥7,014,554,339.23, a 14.33% increase from ¥6,135,507,556.27 at the end of 2021[11]. - The net assets attributable to shareholders increased to ¥6,399,494,567.56, up 14.03% from ¥5,611,998,691.33 in 2021[11]. - The company reported a basic earnings per share of ¥1.6907, a 36.13% increase from ¥1.2420 in 2021[11]. - The total revenue for 2022 reached CNY 3,046,955,734.50, representing a year-on-year increase of 19.70% from CNY 2,545,415,315.72 in 2021[58]. - The revenue from in vitro diagnostics accounted for 99.79% of total revenue, amounting to CNY 3,040,486,867.90, with a year-on-year growth of 19.74%[58]. - The gross margin for reagent products was 89.01%, while for instrument products it was 23.10%[59]. Market Expansion and Product Development - The company expects a compound annual growth rate of 15.38% in the Chinese in vitro diagnostic market from 2020 to 2025[19]. - The global in vitro diagnostic market size is projected to exceed $127.4 billion in 2022, with significant growth in emerging markets like China and India[18]. - The company has sold over 26,500 units of its fully automated chemiluminescence immunoassay analyzers globally, covering nearly 8,700 domestic medical terminals and reaching 151 countries and regions[23]. - The company has launched its first coagulation reagent product, obtaining domestic medical device registration, with a total of 3 coagulation diagnostic reagents registered[27]. - The company has developed four major technology platforms for in vitro diagnostic product research, including nanomagnetic microspheres and automated diagnostic instruments[27]. - The company is focusing on expanding its product line in cardiovascular and inflammatory disease diagnostics with several new reagents[44]. - The company is actively pursuing regulatory approvals for its innovative medical devices to enhance market presence and product offerings[43]. - The company has established a marketing network covering 151 countries and regions, with over 15,100 instruments sold overseas[53]. - The company is expanding its market presence, targeting new regions in Southeast Asia, aiming for a 10% market share by the end of the next fiscal year[107]. Research and Development - R&D expenses rose by 47.74% to ¥317,710,346.15, reflecting increased investment in research and development[65]. - The number of R&D personnel increased by 31.58% to 600, with the proportion of R&D staff rising to 21.29%[67]. - The company has implemented a systematic R&D management framework to enhance innovation capabilities and reduce R&D risks[95]. - The company is currently working on multiple instrument R&D projects, including the Biossays E6 Plus and Molecision R8, with some projects transitioning to production[48]. - The company plans to increase investment in new product development to achieve a strategy of "selling one generation, developing one generation, and reserving one generation" of products[104]. Corporate Governance and Compliance - The company established a governance structure consisting of the shareholders' meeting, board of directors, supervisory board, and management team since its establishment in August 2012[110]. - The board of directors has set up four specialized committees: the Strategy Committee, Audit Committee, Nomination Committee, and Compensation and Assessment Committee to ensure standardized operations and sustainable development[110]. - The company emphasizes investor relations management, utilizing various platforms for effective communication with investors[116]. - The company’s management compensation is directly linked to performance, promoting transparency and accountability[117]. - The company has committed to timely and accurate information disclosure obligations, particularly regarding stock reduction plans after the lock-up period[190]. Risk Management - The company emphasizes the importance of risk factors and countermeasures in its future development outlook, urging investors to pay attention[2]. - The company is adapting to the national medical insurance payment reform, which may impact pricing and sales volume in the in vitro diagnostic sector[24]. - The company faces risks related to policy changes, particularly in the context of centralized procurement reforms that could impact pricing and sales volumes[97]. - The company has established a risk management system for foreign exchange hedging, ensuring that all transactions are based on normal business operations[79]. Shareholder Returns and Dividends - The company plans to distribute a cash dividend of 7.00 RMB per share (including tax) to all shareholders based on the total share capital as of the close of trading on the day of the dividend distribution announcement[2]. - The total cash dividend amount for 2022 is projected to be 550,288,434.50 RMB, based on a total share capital of 786,126,335 shares[161]. - The independent directors confirm the legality and compliance of the profit distribution plan, ensuring the protection of minority shareholders' interests[162]. - The company maintains a stable profit distribution policy, distributing cash dividends of 6 RMB per 10 shares for the 2021 fiscal year, with no stock dividends or capital reserve transfers[158]. Employee Management and Development - The total number of employees at the end of the reporting period is 2,818, including 2,798 in the parent company and 20 in major subsidiaries[153]. - The company has established a competitive salary and incentive system, combining short-term and long-term incentives to attract and retain talent[154]. - The training department was established in 2019, focusing on internal talent development and enhancing employee skills through various training programs[155]. - The company has a total of 6 PhD holders and 459 master's degree holders among its employees, reflecting a strong educational background within the workforce[153]. Environmental and Social Responsibility - The company implemented energy-saving measures, resulting in an 8% reduction in actual electricity consumption compared to expected usage in 2022[177]. - The company established a 100m³ concentrated water recovery pool, saving 8,859.5m³ of water resources in 2022 through the reuse of concentrated water[179]. - The company reduced paper consumption by 25% in 2022, promoting a paperless office initiative[181]. - The company actively participated in charitable donations to support poverty alleviation and rural revitalization, earning the title of "Caring Enterprise"[182].